Your browser doesn't support javascript.
loading
Key clinical beam parameters for nanoparticle-mediated radiation dose amplification.
Detappe, Alexandre; Kunjachan, Sijumon; Drané, Pascal; Kotb, Shady; Myronakis, Marios; Biancur, Douglas E; Ireland, Thomas; Wagar, Matthew; Lux, Francois; Tillement, Olivier; Berbeco, Ross.
Afiliación
  • Detappe A; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, US.
  • Kunjachan S; Lyon-1 University, Institut Lumière Matière, CNRS UMR5306, Lyon, France.
  • Drané P; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, US.
  • Kotb S; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, US.
  • Myronakis M; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, US.
  • Biancur DE; Lyon-1 University, Institut Lumière Matière, CNRS UMR5306, Lyon, France.
  • Ireland T; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, US.
  • Wagar M; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, US.
  • Lux F; LA-ICP-MS and ICP-ES Laboratories, Boston University, Boston, MA 02215, US.
  • Tillement O; Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, US.
  • Berbeco R; Lyon-1 University, Institut Lumière Matière, CNRS UMR5306, Lyon, France.
Sci Rep ; 6: 34040, 2016 Sep 23.
Article en En | MEDLINE | ID: mdl-27658637
As nanoparticle solutions move towards human clinical trials in radiation therapy, the influence of key clinical beam parameters on therapeutic efficacy must be considered. In this study, we have investigated the clinical radiation therapy delivery variables that may significantly affect nanoparticle-mediated radiation dose amplification. We found a benefit for situations which increased the proportion of low energy photons in the incident beam. Most notably, "unflattened" photon beams from a clinical linear accelerator results in improved outcomes relative to conventional "flat" beams. This is measured by significant DNA damage, tumor growth suppression, and overall improvement in survival in a pancreatic tumor model. These results, obtained in a clinical setting, clearly demonstrate the influence and importance of radiation therapy parameters that will impact clinical radiation dose amplification with nanoparticles.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Sci Rep Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Sci Rep Año: 2016 Tipo del documento: Article